Chronic Myeloid Leukemia
Chronic-phase CML patients respond to imatinib, but questions remain
Published in Cancer Weekly, September 2nd, 2003
According to recent research from the United States, "Imatinib mesylate (Gleevec, Glivec, formerly STI571; Novartis Pharmaceuticals) is an inhibitor of the Bcr-abl tyrosine kinase that is central to the pathogenesis of chronic myeloid leukemia (CML).
"The remarkable results of imatinib mesylate in clinical trials have rapidly and profoundly changed the management of patients with CML. This article will review the development of this molecularly targeted agent," wrote B.J. Druker and colleagues, Oregon Health Sciences University Cancer Institute.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2003-09-02)
More Articles from Cancer Weekly
- Genomics
Tumor and drug-resistant genomes can be shaped by instability and selection - Oncology
COX-2 causes prostaglandin E2 to modulate pancreatic cancer angiogenesis - Antisense Technology
Egr-1 inhibition reverses the transformation of prostate cancer cells - Leukemia
Childhood survivors not receiving radiation have same life expectancy as general population - Non-Hodgkin Lymphoma
Delaying chemotherapy could be best treatment option - Pancreatic Cancer
Novel targets for aberrant methylation in pancreatic carcinoma found - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
